NorthWest Biotherapeutics Inc (NWBO)

[heads]

https://www.evaluate.com/vantage/articles/analysis/spotlight/hope-versus-experience-glioblastoma

Notorious for its lack of progress is Northwest Biotherapeutics’ DCVax-L. In October the company said it had locked the database for its long-running – 14 years, according to clinicaltrials.gov – phase III trial of this cancer vaccine. A release of data could be imminent, but there has been no movement here for at least eight years, and many industry watchers have long since run out of patience.

With at least three therapies under investigation, the GBM Agile trial will be a major watershed in the development of glioblastoma therapies when it reports in a couple of years. Until then, Laminar’s Clinglio study is the one to watch – unless, of course, Northwest Bio defies the doomsayers with knockout data for DCVax-L.